Drug Trial Radar · NCT07277413
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
260
Planned (sponsor's estimate)
Start
Mar 4, 2026
Primary completion
Apr 30, 2028
Study completion Apr 30, 2028
Sponsor
- Lead sponsor
- IDEAYA BiosciencesIndustry
- Sponsor type
- Industry
- First posted
- Dec 11, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter clinical study to evaluate the safety, efficacy, and Pharmacokinetics (PK) of IDE892 as monotherapy and in combination with other agents including IDE397 in participants with methylthioadenosine phosphorylase (MTAP)-deleted advanced solid tumors within indications of interest.
Conditions
- NSCLC Adenocarcinoma
- Gastroesophageal Cancer (GC)
- Gastric Adenocarcinoma
- Adenocarcinoma of Esophagus
- Squamous Cell Car. - Esophagus
- Urothelial Carcinoma (UC)
- Bladder Cancer
- Mesothelioma
- Pleural Mesothelioma
- Peritoneal Mesothelioma
- Non-Small Cell Lung Cancer NSCLC
- Pancreatic Cancer
- Biliary Tract Carcinoma
Interventions
IDE892Drug
IDE892 is an inhibitor of the Protein arginine methyltransferase 5 (PRMT5) that is being developed by IDEAYA Biosciences, Inc. as an anticancer therapeutic for patients with advanced or metastatic cancer harboring MTAP deletions.
IDE397Drug
IDE397 is an oral MAT2A inhibitor that is being developed by IDEAYA Biosciences, Inc. as an anticancer therapeutic for patients with advanced or metastatic cancer harboring MTAP deletions. In this study, IDE397 will be evaluated in combination with IDE892 (Parts 3 and 4) in participants with MTAP-deleted advanced solid tumors.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Dose-limiting Toxicities (DLTs) of IDE892 (Parts 1 and 3)Time frame: 21 days following the first dose of IDE892 (each cycle is 21 days)
- Incidence of AEs and SAEs (Parts 1, 2, 3, and 4)Time frame: From first dose until 28 days after last dose (each cycle is 21 days)
- Objective response rate (ORR) and duration of response (DOR) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 (Parts 2 and 4)Time frame: Approximately 2 years
Locations
26 sites in 2 countries. Site status is shown where the registry gives one.
City of Hope Cancer Center-Phoenix
Goodyear, Arizona · Recruiting
Mayo Clinic Arizona
Phoenix, Arizona · Recruiting
City of Hope Cancer Center-Duarte
Duarte, California · Recruiting
Providence Medical Foundation
Santa Rosa, California · Recruiting
Johns Hopkins Sibley Memorial Hospital
Washington D.C., District of Columbia · Recruiting
BRCR Global-Coral Springs
Coral Springs, Florida · Recruiting
Mayo Clinic Florida
Jacksonville, Florida · Recruiting
Sarah Cannon Research Institute at Florida Cancer Specialists
Orlando, Florida · Recruiting
Moffitt Cancer Center
Tampa, Florida · Recruiting
City of Hope Cancer Center-Chicago
Zion, Illinois · Recruiting
Mayo Clinic Rochester
Rochester, Minnesota · Recruiting
Nebraska Cancer Specialists
Omaha, Nebraska · Recruiting
START Astera, LLC
East Brunswick, New Jersey · Recruiting
Columbia University Irving Medical Center
New York, New York · Recruiting
Sidney Kimmel Comprehensive Cancer Center Thomas Jefferson University
Philadelphia, Pennsylvania · Recruiting
Sarah Cannon Research Institute
Nashville, Tennessee · Recruiting
START Dallas Fort Worth
Fort Worth, Texas · Recruiting
MD Anderson
Houston, Texas · Recruiting
NEXT Oncology Houston
Houston, Texas · Recruiting
NEXT Oncology Dallas
Irving, Texas · Recruiting
START Mountain Region, LLC
West Valley City, Utah · Recruiting
NEXT Oncology Virginia
Fairfax, Virginia · Recruiting
Swedish Cancer Institute
Seattle, Washington · Recruiting
Samsung Medical Center
Seoul, South Korea · Recruiting
CHA Bundang Medical Center
Seongnam-si, Gyeonggi-do, South Korea · Recruiting
Chungbuk National University Hospital
Cheongju-si, North Chungcheong, South Korea · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.